ELIMITE
Drug
Mayne Pharma Inc.
Total Payments
$388,911
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $388,911 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $388,911 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Permethrin Bioequivalence | Mayne Pharma Inc. | $388,911 | 0 |
Top Doctors Receiving Payments for ELIMITE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Richland, WA | $388,911 | 4 |
Ad
Manufacturing Companies
- Mayne Pharma Inc. $388,911
Product Information
- Type Drug
- Total Payments $388,911
- Total Doctors 0
- Transactions 4
About ELIMITE
ELIMITE is a drug associated with $388,911 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Mayne Pharma Inc..
Payment data is available from 2017 to 2017. In 2017, $388,911 was paid across 4 transactions to 0 doctors.
The most common payment nature for ELIMITE is "Unspecified" ($388,911, 100.0% of total).
ELIMITE is associated with 1 research study, including "Permethrin Bioequivalence" ($388,911).